Karyopharm Therapeutics (NASDAQ:KPTI) PT Lowered to $5.00
Karyopharm Therapeutics (NASDAQ:KPTI) PT Lowered to $5.00
Karyopharm Therapeutics (NASDAQ:KPTI – Get Rating) had its price target decreased by analysts at Morgan Stanley from $7.00 to $5.00 in a note issued to investors on Friday, Benzinga reports. The firm presently has an "equal weight" rating on the stock. Morgan Stanley's price target points to a potential upside of 56.74% from the company's current price.
据Benzinga报道,在周五发布给投资者的一份报告中,摩根士丹利的分析师将卡拉帕姆治疗公司(纳斯达克:KPTI-GET评级)的目标价从7.00美元下调至5.00美元。该公司目前对该股的评级为“同等权重”。摩根士丹利的目标股价表明,该公司目前的股价有56.74%的潜在上行空间。
KPTI has been the topic of a number of other reports. HC Wainwright lowered their price target on shares of Karyopharm Therapeutics from $18.00 to $16.00 and set a "buy" rating on the stock in a research report on Tuesday, January 10th. StockNews.com cut Karyopharm Therapeutics from a "hold" rating to a "sell" rating in a report on Wednesday, November 30th. Piper Sandler initiated coverage on Karyopharm Therapeutics in a research report on Thursday, January 19th. They issued an "overweight" rating and a $8.00 price target on the stock. SVB Leerink cut their price objective on shares of Karyopharm Therapeutics from $6.00 to $5.00 and set a "market perform" rating for the company in a research report on Tuesday, January 10th. Finally, Royal Bank of Canada raised shares of Karyopharm Therapeutics from a "sector perform" rating to an "outperform" rating and raised their target price for the company from $7.00 to $10.00 in a report on Friday, November 4th. One analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $9.33.
KPTI一直是其他一些报告的主题。HC Wainwright在1月10日(星期二)的一份研究报告中将Karyopamm治疗公司的股票目标价从18.00美元下调至16.00美元,并对该股设定了“买入”评级。在11月30日星期三的一份报告中,StockNews.com将Karyopharm治疗公司的评级从“持有”下调至“卖出”。派珀·桑德勒在1月19日星期四的一份研究报告中提出了对Karyopamm治疗公司的报道。他们对该股给予了“增持”评级和8.00美元的目标价。SVB Leerink在1月10日(星期二)的一份研究报告中将Karyopamm治疗公司的股票目标价从6.00美元下调至5.00美元,并为该公司设定了“市场表现”评级。最后,加拿大皇家银行在11月4日(周五)的一份报告中将Karyopamm治疗公司的股票评级从“行业表现”上调至“表现优于大盘”,并将该公司的目标价从7.00美元上调至10.00美元。一名分析师对该股的评级为卖出,三名分析师给出了持有评级,五名分析师给出了该公司的买入评级。根据MarketBeat.com的数据,该股目前的平均评级为持有,共识目标价为9.33美元。
Karyopharm Therapeutics Stock Up 1.9 %
卡拉帕姆治疗公司股票上涨1.9%
Shares of Karyopharm Therapeutics stock traded up $0.06 on Friday, hitting $3.19. The stock had a trading volume of 267,941 shares, compared to its average volume of 3,391,519. The stock has a market cap of $258.88 million, a price-to-earnings ratio of -2.80 and a beta of 0.03. Karyopharm Therapeutics has a twelve month low of $2.45 and a twelve month high of $14.73. The business's 50 day moving average is $3.71 and its two-hundred day moving average is $4.57.
卡里奥帕姆治疗公司的股票周五上涨0.06美元,达到3.19美元。该股成交量为267,941股,而其平均成交量为3,391,519股。该股市值为2.588亿美元,市盈率为-2.80倍,贝塔系数为0.03。卡罗帕姆治疗公司的12个月低点为2.45美元,12个月高位为14.73美元。该业务的50日移动均线切入位在3.71美元,200日移动均线切入位在4.57美元。
Institutional Trading of Karyopharm Therapeutics
卡拉帕姆治疗药物的制度性交易
A number of hedge funds have recently made changes to their positions in the company. Dupont Capital Management Corp bought a new position in Karyopharm Therapeutics in the 4th quarter valued at approximately $78,000. Bank of New York Mellon Corp grew its stake in shares of Karyopharm Therapeutics by 4.4% in the third quarter. Bank of New York Mellon Corp now owns 298,991 shares of the company's stock worth $1,632,000 after purchasing an additional 12,610 shares during the last quarter. Balyasny Asset Management LLC increased its holdings in Karyopharm Therapeutics by 592.0% in the third quarter. Balyasny Asset Management LLC now owns 595,558 shares of the company's stock valued at $3,252,000 after purchasing an additional 509,499 shares during the period. BNP Paribas Arbitrage SNC increased its holdings in Karyopharm Therapeutics by 30.5% in the third quarter. BNP Paribas Arbitrage SNC now owns 762,520 shares of the company's stock valued at $4,163,000 after purchasing an additional 178,232 shares during the period. Finally, Alliancebernstein L.P. raised its position in Karyopharm Therapeutics by 17.0% during the 3rd quarter. Alliancebernstein L.P. now owns 138,130 shares of the company's stock worth $754,000 after purchasing an additional 20,100 shares during the last quarter. 96.13% of the stock is owned by institutional investors and hedge funds.
一些对冲基金最近改变了他们在该公司的头寸。杜邦资本管理公司在第四季度购买了卡里奥帕姆治疗公司的一个新头寸,价值约7.8万美元。第三季度,纽约梅隆银行(Bank Of New York Mellon Corp)在Karyopamm Treeutics的持股增加了4.4%。纽约梅隆银行(Bank Of New York Mellon Corp)目前持有298,991股该公司股票,价值1,632,000美元,此前该公司在上一季度又购买了12,610股。Balyasny Asset Management LLC在第三季度增持了592.0%的卡里奥帕姆治疗公司的股份。Balyasny Asset Management LLC在此期间又购买了509,499股,现在拥有595,558股该公司股票,价值3,252,000美元。法国巴黎银行套利SNC在第三季度增持Karyopamm治疗公司30.5%的股份。法国巴黎银行套利SNC在此期间又购买了178,232股,现在拥有762,520股该公司股票,价值4,163,000美元。最后,联合伯恩斯坦公司在第三季度将其在Karyopamm治疗公司的头寸提高了17.0%。联合伯恩斯坦公司在上个季度又购买了20,100股股票后,现在持有138,130股该公司股票,价值754,000美元。96.13%的股票由机构投资者和对冲基金持有。
About Karyopharm Therapeutics
关于卡拉帕姆治疗学
(Get Rating)
(获取评级)
Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1.
卡尔奥帕姆治疗公司是一家商业阶段的制药公司,发现、开发和商业化针对核出口的药物,用于治疗癌症和其他疾病。该公司通过与核出口蛋白XPO1结合并抑制其功能,发现、开发和商业化新型选择性核出口(SINE)抑制剂化合物。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Karyopharm Therapeutics (KPTI)
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
- PCE Indicates Slowdown In Spending, Economy Weakens
- Microsoft's Comeback Is Now Underway
- Can Amazon Recover Amid Tech Stock Sell-off?
- 免费获取StockNews.com关于Karyopamm治疗(KPTI)的研究报告
- ASML预计今年芯片需求回升,提振销售观点
- KLA公司:在动荡不安的半市场中站稳脚跟
- PCE表明支出放缓,经济疲软
- 微软的卷土重来正在进行中
- 在科技股抛售中,亚马逊能否复苏?
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《红毛丸治疗日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯,接收最新新闻和分析师对Karyopharm治疗公司和相关公司评级的每日简要摘要。